Wednesday, November 11, 2026

Enterprise AI Applications

4 articles

Enterprise Finance Software Adds AI Agents as CFOs Plan Spending Increases

Enterprise Finance Software Adds AI Agents as CFOs Plan Spending Increases

Oracle Fusion and OneStream are deploying agentic AI applications in finance software as CFO technology budgets shift toward AI. Finance Pilot launched automated trading systems using machine learning algorithms. The moves reflect enterprise adoption of AI automation across financial operations and trading workflows.

LM Salvado•
ESET Security Software Cuts CPU Usage 72% Through Intel AI Integration

ESET Security Software Cuts CPU Usage 72% Through Intel AI Integration

ESET PROTECT reduced CPU utilization by 72% and background activity by 86% after integrating Intel Threat Detection Technology. The cybersecurity platform achieved Intel vPro Certified App status while maintaining detection efficacy through processor-level AI threat analysis.

LM Salvado•
CFOs Plan 50%+ AI Budget Increases as OneStream Launches Automated Trading Platform

CFOs Plan 50%+ AI Budget Increases as OneStream Launches Automated Trading Platform

Nearly 25% of CFOs plan to increase AI spending by more than 50%, according to OneStream survey data released alongside the company's Finance Pilot AI trading platform launch. The enterprise finance software provider is restructuring leadership while rolling out automated decision-making tools for financial operations.

LM Salvado•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com